




Genetic Epidemiology at the intersection between function and disease

Florian Kronenberg

Institute of Genetic Epidemiology, Medical University of Innsbruck

1


Overview

- 1. Background**
2. Association studies
3. Genomewide association studies (GWAS)

The logo for GENEPI INNSBRUCK, featuring the text "GENEPI" in a larger, bold font above "INNSBRUCK" in a smaller font, with a stylized blue and white graphic to the left.

2

How is health and disease determined?



GENEPI
INNSBRUCK

3

Why are we interested in "new" genes?

By Victor A. McKusick, M.D., Baltimore,
Maryland

Ann. Int. Med. 49:556-567, 1958

Study of genetic factors is important:

- (1) because potentially it will permit recognition of genetic susceptibles, for more effective application of preventive measures,



"Bummer of a birthmark, Hal."

GENEPI
INNSBRUCK

4

Why are we interested in "new" genes?


By Victor A. McKusick, M.D., Baltimore, Maryland

Ann. Int. Med. 49:556-567, 1958

Study of genetic factors is important:

- (2) because from our **understanding of the mechanism** whereby the gene or genes operate in these disorders can come preventive or therapeutic measures for breaking the chain leading to disease.

Drug target?




"This could be the discovery of the century. Depending, of course, on how far down it goes."


GENEPI
INNSBRUCK

5

Monogenic and complex diseases



Monogenic diseases:
e.g. Morbus Huntington



Complex diseases:
e.g. Diabetes, myocardial infarction, overweight, cancer, ...

Environmental factors are e.g. smoking, physical activity, nutrition, education, sun exposition,

GENEPI
INNSBRUCK

6

Knockout versus small changes by polymorphisms

Knock-out



- Pronounced effects
- Animals: great models but not necessarily to extrapolate to humans
- Humans: often very rare cases

Polymorphism



- Small effects
- Usually investigated in humans
- Real in vivo conditions
- Thousands of people can be studied easily
- Sample sizes of thousands are required

GENEPI
INNSBRUCK

7

Genetic variability

GTGGTGTACATAAATGCGT



GTGGTGTACGTAAATGCGT

A) Single Nucleotide Polymorphism (SNP)

GTGGTGTACATAAATGCGT




GTGGTGTAAAAATGCGT

B) Indel aka. DIP

AGATGAGAGAGAGAGTCC

AGATGAGAGAGTCC

C) Short Tandem Repeat (STR)




D) Copy Number Variation (CNV)
Size >1 Kb

GENEPI
INNSBRUCK

8

Single Nucleotide Polymorphisms (SNPs)

- Variations of single base pairs (bp) in the DNA sequence
- Heritable and stable.
- Account for 90% of the genetic variability
- Every 300 – 1000 bp
- At least 3 – 4 million SNPs per individual
- 10,000 – 11,000 non-synonymous SNPs per individual
- 700 million SNPs are described in databases



GENEPI
INNSBRUCK

9

Single Nucleotide Polymorphism (SNP)

- Coding SNPs within a gene
 - synonymous exchanges: without influence on protein
 - non-synonymous exchanges: resulting in an AA exchange
- SNPs within the regulatory regions:
 - when and why a gene will be switched on or off
 - effect on quantity of protein production
- SNPs within the untranslated regions
 - with influence on mRNA stability
- SNPs in intergenic regions
 - functional consequences have to be evaluated

GENEPI
INNSBRUCK

10

Some basics from epidemiology

■ Odds ratio

- ▶ Represents the odds that an outcome will occur given a particular exposure, compared to the odds of the outcome occurring in the absence of that exposure.
- ▶ Values between 0 and infinite (∞)
- ▶ 1.00 = same odds
- ▶ 1.50 = 50% higher odds
- ▶ 2.00 = 100% higher odds
- ▶ 0.50 = 50% lower odds


■ 95% confidence interval (CI)

■ Hazard ratio

- ▶ In case of prospective studies

■ Meta-analysis

- ▶ Combining data from more than one study




Overview

1. Background
2. Association studies
3. Genomewide association studies (GWAS)

Principle of association studies


Qualitative analysis:

Preferential association of an allele with a disease status



Cases (e.g. diabetes)


Controls



Allele ● 3 times more frequent in cases

Quantitative analysis:

Carriers of a various alleles differ in the mean values of the investigated parameter (e.g. cholesterol level)




GENEPI
INNSBRUCK

13

Remember: crossover and recombination during meiosis I

No recombination of alleles of the gene loci A and B since crossover outside the region between A and B



Recombination of alleles in the two gametes due to crossover


"Wanted" disease locus

Genotyped marker locus

Jorde, Carey, Bamshad, White: Medical Genetics


14

Basis of association: Linkage disequilibrium



	Patients	Controls
Allele 2A	90%	50%
Allele 1C	78%	50%

After many generations




R ... Recombination

GENEPI
INNSBRUCK

15

Indirect association



**Disease-causing variant
we are searching**

ACTAGA**G**CTACTACGAGGGACTAC...TACGAGCATC**G**ACTA...GAGG
TAGAGCT**A**TA...TTCT**A**GGCTA...CTACGAT**C**GATC...ACGT**A**G...


High correlation

The genotyped SNP is a marker of the „non-genotyped“
disease-causing variant we are searching

GENEPI
INNSBRUCK

The investigated genetic variant
is in linkage disequilibrium with
the causal variant

Due to the small distance there are
rarely crossovers and
recombinations during meiosis




**Allele A can be observed
more frequently in the
diseased group**


16

Mendelian Randomization study: a great tool to support causality

Biomarker for diseases: causality or consequence?




Biomarker for diseases: causality or consequence?



The big question for biomarkers

- You found an association with a disease
- **Risk factor or risk marker?**
- Classical epidemiological studies with prospective observation will last a long time and will not prove causality
- You have to decide now whether to go for drug development or not
- Worst case scenario: after 10-15 years of development the drug flops
- One reason might be that it is only a risk marker and not a risk factor.

Example of a flop: CETP inhibitors




GENEPI
INNSBRUCK

Kronenberg: Kidney Int. 89:747-9, 2016

21


Mendelian randomization approach



GENEPI
INNSBRUCK

22


Mendelian randomization approach



GEIPEI
INNSBRUCK

23

Mendelian randomization at the time of conception




GEIPEI
INNSBRUCK

Adapted from Cardiovasc. Drugs
Ther. 30:87-100, 2016

24

ApoE, cholesterol and risk for CVD



25

Example: Lipoprotein(a) - Lp(a)

The first example in history
a Mendelian randomization study has been performed
(in the early 1990-ies)

26


Experience of a young widow

- Husband 39 years of age
- Loses consciousness, cardiac arrest, revival not successful
- No classical risk factors
- Healthy lifestyle, physically active
- Health checkup on a yearly basis
- Autopsy: most severe heart disease
- **Very high Lp(a) concentrations**

GENEPI
INNSBRUCK

27

Lp(a) - the next target to fight cardiovascular disease




GENEPI
INNSBRUCK

28

- Described by K. Berg in 1963
- Concentrations are mainly genetically determined
- Shows only minor correlations with other lipoproteins (if any)
- An independent and one of the most important genetic cardiovascular risk factors
- One Lp(a) particle is about 6 times more atherogenic than one LDL particle


The association between Lp(a) and major CVD* outcomes is continuous independent of ethnicity → Lp(a) measurement is relevant globally



The higher the concentrations the higher the risk

Lp(a) - association with various CVD endpoints

Data from Copenhagen studies




Enormous public health relevance:

- These endpoints are frequent
- High Lp(a) concentrations are frequent
- Similar population-attributable risk as smoking, diabetes and hypercholesterolemia


Please do not get confused by the two units! Never name an Lp(a) concentration without the unit!

Strong support for causality by Mendelian randomization studies




Kronenberg & Utermann: J. Int. Med. 273: 6-30, 2013


31



32



33




34

EAS Consensus panel recommendations for Lp(a) testing

- Lp(a) should be measured at least once in all adults to identify those with high cardiovascular risk
- Check the family in case of high Lp(a) of the index patient since Lp(a) concentrations is genetically determined
- Genetic testing is not required




Lp(a) concentrations and cardiovascular risk



* Traditional risk factors are age, sex, blood cholesterol, blood pressure, smoking, diabetes, a family history of heart attacks in early life and body mass index

Lp(a) concentrations and cardiovascular risk



→ If Lp(a) level is not considered in risk estimation, ASCVD risk might be underestimated substantially

GENEPI
INNSBRUCK

37

Lp(a) Global Summit
International Task Force
24 - 25 March 2025 | Brussels, Belgium

Logos: EAS, Global Heart Hub, International Atherosclerosis Society, World Heart Federation, etc.

Endorse the declaration



Patronage of the Polish EU presidency

Key opinion leaders
in the Lp(a) field

People with lived
experience of high Lp(a)

Members of the EU-
Parliament

Members of the WHO,
EAS, IAS, WHF

**Cost-effectiveness
analysis of Lp(a)
testing**

NEW

Contents lists available at ScienceDirect

Atherosclerosis

journal homepage: www.elsevier.com/locate/atherosclerosis

The Brussels International Declaration on Lipoprotein(a) Testing and Management

atherosclerosis

Volume 312, 1-2, 2022

ISSN 0954-6820

0954-6820(2022)312:1-2;1-2

1-2

1-2

1-2

1-2

1-2

1-2

1-2

1-2

1-2

1-2

1-2

1-2

1-2

1-2

1-2


1-2

1-2


1-2

1-2

38




39



40

Costs saved per person



Morton et al.: Atherosclerosis: <https://doi.org/10.1016/j.atherosclerosis.2025.120447>

provided by Prof. Zanfina Ademi

atherosclerosis

Morton et al.: Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis

41

Key asks of the Brussels International Declaration on Lp(a) Testing and Management



Lp(a) should be part of Cardiovascular Health Plans



Policy and programmes for Lp(a) testing and management to save costs



Political Leadership and Commitment for systematic Lp(a) testing with full reimbursement



Global Cardiovascular Risk Assessment including Lp(a)



Raising Awareness about Lp(a)

Details can be found here:

<https://doi.org/10.1016/j.atherosclerosis.2025.119218>



Lp(a) Global Summit
International Task Force

You can endorse the Brussels International Declaration at:

<https://fhf.org/brussels-international-declaration/>



Each vote is a signal

atherosclerosis

Kronenberg et al.:

The Brussels International Declaration on Lp(a) Testing and Management


42

Overview

1. Background
2. Association studies
3. **Genomewide association studies (GWAS)**

Candidate gene approach vs. GWAS

Candidate gene approach



Association with phenotype

- Hypothesis-driven
- Biochemical or physiological *a priori* knowledge
- Few genes identified

Candidate gene approach vs. GWAS

Candidate gene approach




Association with phenotype

- Hypothesis-driven
- Biochemical or physiological *a priori* knowledge
- Few genes identified

Genomewide association study

GWAS



Association with phenotype

- **"Hypothesis-free"** (unbiased)
- No *a priori* knowledge
- New pathways
- Small effects detectable
- **Very large sample sizes required**

GENEPI
INNSBRUCK


45

2018 Apr

Associations: 69,885

Studies: 5,152

Papers: 3,378



www.ebi.ac.uk/gwas

46

Gain in detected genes by GWAS

Examples for metabolic traits




Disease	before 2007	2007 onward
Type 2 DM	3	50
Body mass index	1	30
Glucose or insulin	1	15
Fat distribution	0	20
Lipids	16	95
Total	21	202

7 examples of autoimmune diseases

Disease	before 2007	2007 onward
Ankylosis spondylitis	1	13
Rheumatoid arthritis	3	30
Systemic lupus eryth.	3	31
Type 1 DM	4	40
Multiple sclerosis	1	51
Crohn's disease	4	67
Ulcerative colitis	3	44
Total	19	277

Since 2012 the number of known genes has further increased by 5- to 10-fold

Design and cost-performance ratio



- Costs per array: 30-150 €
- You genotype only once and then do the GWAS for all phenotypes you have for the cohort

Association with phenotypes (e.g.)

- BMI
- Waist
- Blood pressure
- QT interval
- Smoking

Lab values


- Lipids
- Kidney function
- CRP
- Hemoglobin
- ...

Diseases

- CAD
- Stroke
- Ankle-brachial-index
- Cancer types

Whatever has a genetic component and is measured

The Manhattan Plot



GENEPI
INNSBRUCK

Schunkert et al.: Nature Genetics 43:333-338, 2011

49

Genome-wide association studies (GWAS)

■ Examples:

- ▶ Lipids
- ▶ Type 2 diabetes mellitus
- ▶ Blood pressure
- ▶ BMI

GENEPI
INNSBRUCK

50

GWAS: Lipids

■ Consortium:


- ▶ Established during fall 2005
- ▶ Together with Helmholtz-Zentrum München
- ▶ 11 members studying various phenotypes

■ Innsbruck Group:

- ▶ Lipid metabolism
- ▶ HDL-C as a starting point
- ▶ Quantitative trait considered more powerful

■ Population and Genotyping:

- ▶ 1644 population-based subjects from KORA
- ▶ Affymetrix 500K SNP chip



GENEPI
INNSBRUCK

Iris Heid

Stefan Coassin

Eva Boes


Barbara Kollerits

Anita Brandstätter

Claudia Lamina

51

GWAS: HDL cholesterol



GENEPI
INNSBRUCK

Heid et al.: Circ. Cardiovasc. Genet. 1:10-20, 2008

52

GWAS on Lipids (TC, HDLC, LDLC, TG): next steps


- **First own GWAS** (*Circ. Cardiovasc. Genet.* 2008)
 - 1644 probands: found nothing new
- **Engage Consortium:** (*Nature Genetics* 2009)
 - ▶ 22,000 probands: **22 genes found associated**
- **Global Lipids Genetics Consortium:** (*Nature* 2010)
 - ▶ >100,000 probands: **95 genes found associated**
- **Global Lipids Genetics Consortium:** (*Nature Genetics* 2013)
 - ▶ >188,000 probands: **roughly 155 genes found associated**
- **Global Lipids Genetics Consortium:** (*Nature* 2021)
 - ▶ 1,65 million probands: **>900 Gene**

- The more individuals you investigate, the more genes you will find
- Functional characterisation for most of the genes has to be done

GENEPI
INNSBRUCK

53

GWAS: Type 2 diabetes mellitus



2017:
≈ 86 genes

2019:
≈ 250 genes


GENEPI
INNSBRUCK

T. Frayling:
Nat.Rev.Genet. 8:657-62, 2007

54

GWAS and blood pressure traits

- Phenotypes: systolic and diastolic BP, pulse pressure
- > 1 million study participants
- 901 genetic loci in total (535 novel)



GENEPI
INNSBRUCK

Evangelou et al.: Nature Genet. 50:1412-25, 2018

55

Genes for body mass index and overweight

Own behavior (lifestyle)



GENEPI
INNSBRUCK

Genetics

- ▶ 536 genetic loci detected
- ▶ Many of them play a role in the brain by
 - ⇒ **Regulation of appetite**
 - ⇒ Neuronal component of overweight
- ▶ Explain roughly 5% of BMI


56

Contribution of single genes to overweight

- **Very few with strong effects:** risk increase by 10 to 30% per allele
- **More with moderate effects:** risk increase by 3 to 10% per allele
- **Many more with tiny effects:** risk increase by 0.1 to 3% per allele

Development of SNP-Risk-Scores

Risk score of 97 SNPs for BMI: 0-194 risk variants



GENEPI
INNSBRUCK

Shungin et al., Nature, 2015

59

Risk score for 65 SNPs for diabetes



Many risk variants
(top quintile)

2.7-fold increased
risk to develop a
diabetes in the
future

Few risk variants
(bottom quintile)

GENEPI
INNSBRUCK

Talmud et al., Diabetes 64:1830-40, 2015

60


Where is the reward?

Can a single gene explaining less than 1% of the traits' variance still be useful for anything?

Statins: HMG-CoA-Reductase-Inhibitors

■ Mechanism of action

- ▶ Inhibition of HMG-CoA-Reductase: this enzyme catalyzes the conversion of HMG-CoA to mevalonic acid: an early and rate-limiting step in cholesterol biosynthesis.
- ▶ Results in higher expression of LDL receptor which decreases LDL cholesterol



Polymorphisms in HMG-CoA-R gene region

■ GWAS results for HMG-CoA-reductase

- ▶ Very small effects
- ▶ Were not detected in the first GWAS
- ▶ This gene was only detected after investigation of at least 10.000 subjects
- ▶ Single polymorphisms explain far less than 1% of the cholesterol concentrations within a population
- ▶ Nevertheless, the most successful drug target for lipid metabolism

■ Other drug targets within the 900 lipid genes?

- ▶ CETP, ABCA1, PCSK9
- ▶ Others?

Conclusions on GWAS

- An hypothesis-free approach
- Never before such a gain in gene-phenotypic information
- New genes for CAD, diabetes, cancer, kidney function...
- Odds ratios between 1.02 and 1.40
- To have the equipment is only the smallest step
- Very large studies of well phenotyped cohorts are necessary
- Works only within a very well constructed network between genetics, epidemiology, statistics, informatics, genomics
- Data sharing (a lot is already on the web)
- Non-coding SNPs and "gene deserts" can no longer be neglected
- A lot to learn about regulatory regions
- Functional characterization of "new" genes will need decades

Why are we searching these many genes?

Improvement of risk prediction (genetic risk scores)

Identification of new drug targets

- ▶ PCSK9 increases LDL cholesterol: discovered by genetic studies
- ▶ PCSK9 inhibitors lower LDL cholesterol by 60%

Exclusion of drug targets

- ▶ CETP increases the "good" cholesterol
- ▶ Development of CETP inhibitors to increase HDL cholesterol
- ▶ Billions of investment without lowering of heart attacks
- ▶ Genetic studies would have predicted the failure of these drugs
- ▶ Newer developments of CETP-inhibitors lower LDL-C and Lp(a)

Gene hunting: an interdisciplinary approach

